Raymond James & Associates Sells 19,888 Shares of Guardant Health, Inc. (NASDAQ:GH)

Raymond James & Associates trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 13.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,464 shares of the company’s stock after selling 19,888 shares during the period. Raymond James & Associates owned about 0.13% of Guardant Health worth $3,576,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GH. Price T Rowe Associates Inc. MD lifted its stake in Guardant Health by 1.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,594,599 shares of the company’s stock worth $85,839,000 after acquiring an additional 23,857 shares during the period. California Public Employees Retirement System lifted its position in shares of Guardant Health by 24.8% during the third quarter. California Public Employees Retirement System now owns 200,607 shares of the company’s stock valued at $10,799,000 after buying an additional 39,829 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Guardant Health during the third quarter valued at about $213,000. Laurel Wealth Advisors Inc. purchased a new stake in shares of Guardant Health during the third quarter valued at about $227,000. Finally, International Biotechnology Trust PLC lifted its holdings in shares of Guardant Health by 2,379.2% during the 3rd quarter. International Biotechnology Trust PLC now owns 74,500 shares of the company’s stock valued at $4,004,000 after purchasing an additional 71,495 shares during the last quarter. 90.43% of the stock is currently owned by institutional investors.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy bought 8,600 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was bought at an average price of $26.15 per share, with a total value of $224,890.00. Following the completion of the purchase, the chief executive officer now directly owns 2,049,238 shares in the company, valued at $53,587,573.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Guardant Health news, CEO Helmy Eltoukhy bought 8,600 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was bought at an average price of $26.15 per share, with a total value of $224,890.00. Following the completion of the purchase, the chief executive officer now directly owns 2,049,238 shares in the company, valued at $53,587,573.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amirali Talasaz bought 40,000 shares of the business’s stock in a transaction on Monday, March 13th. The shares were acquired at an average cost of $25.66 per share, with a total value of $1,026,400.00. Following the purchase, the chief executive officer now owns 1,893,845 shares of the company’s stock, valued at $48,596,062.70. The disclosure for this purchase can be found here. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley reduced their target price on Guardant Health from $73.00 to $66.00 and set an “overweight” rating on the stock in a research report on Monday, February 27th. UBS Group assumed coverage on Guardant Health in a research report on Friday, May 5th. They set a “buy” rating and a $40.00 target price on the stock. Piper Sandler reduced their target price on Guardant Health from $35.00 to $30.00 in a research report on Monday, May 15th. JPMorgan Chase & Co. reduced their target price on Guardant Health from $75.00 to $65.00 and set an “overweight” rating on the stock in a research report on Friday, February 24th. Finally, Credit Suisse Group reduced their target price on Guardant Health from $60.00 to $55.00 in a research report on Wednesday, May 10th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Guardant Health Stock Performance

NASDAQ GH opened at $27.87 on Friday. The company has a market cap of $2.86 billion, a PE ratio of -4.29 and a beta of 0.82. The stock’s 50 day simple moving average is $24.98 and its 200-day simple moving average is $31.61. Guardant Health, Inc. has a 1-year low of $20.67 and a 1-year high of $62.75. The company has a debt-to-equity ratio of 18.90, a current ratio of 5.41 and a quick ratio of 5.18.

Guardant Health (NASDAQ:GH – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The company reported ($1.36) EPS for the quarter, beating the consensus estimate of ($1.40) by $0.04. Guardant Health had a negative return on equity of 530.36% and a negative net margin of 137.90%. The firm had revenue of $126.89 million during the quarter, compared to analysts’ expectations of $125.43 million. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -4.73 EPS for the current fiscal year.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.